Hyundai Motor Group Tops 2025 J.D. Power U.S. Initial Quality Study
Hyundai Motor Group ranks No.1 among all corporations in the J.D. Power…
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward…
Radware Schedules Conference Call for Its Second Quarter 2025 Earnings
TEL AVIV, Israel, July 02, 2025 (GLOBE NEWSWIRE) -- Radware® (NASDAQ: RDWR),…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET Â | Source: Instil Bio US phase 1…
Kia Announces June 2025 Global Sales Results
June 2025 global sales of 269,652 units, up 0.2% Y/yOutside of Korea,…
Rockefeller Foundation Supports BRAC to Empower Smallholder Farmers Across Asia and Africa
Through the 300,000 USD grant, BRAC will develop a program that aims…
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss…
MSCI Announces the Results of the MSCI 2025 Global Market Accessibility Review
NEW YORK--(BUSINESS WIRE)--MSCI Inc. (NYSE: MSCI), a leading provider of critical decision…
